Recent Finacing
Recent Raise
Aerovate develops AV-101, an inhaled dry‑powder imatinib for pulmonary arterial hypertension that delivers drug to lungs to reduce systemic exposure and improve tolerability versus oral/nebulized therapies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Aerovate Therapeutics.
